TelosRX explains what retatrutide clinical trial results actually show: a triple-agonist GLP-1 compound that outperformed both semaglutide and tirzepatide benchmarks in phase 2 data, with phase 3 cardiovascular outcomes trials now underway. Subject to medical approval by a licensed provider.
Retatrutide is not a household name yet. But the clinical data behind it may reshape how obesity medicine approaches patients who plateau on existing GLP-1 therapy. This article walks through what published trials and meta-analyses have actually reported — no hype, no guarantees, just the evidence.
What Is Retatrutide?
Retatrutide (LY3437943, developed by Eli Lilly) is a once-weekly injectable that activates three receptors simultaneously: GLP-1, GIP, and glucagon. That triple mechanism sets it apart from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP).
Its extended pharmacokinetic half-life of roughly one week supports weekly subcutaneous dosing. GLP-1 activation suppresses appetite and slows gastric emptying. GIP amplifies the insulin response. Glucagon agonism increases hepatic fatty acid oxidation and lipolysis — a metabolic lever neither semaglutide nor tirzepatide pulls directly.
As of 2026, compounded retatrutide is not FDA-approved. It is available through telehealth pharmacies subject to evaluation by a licensed provider, and it is prepared under federal compounding regulations, not as an FDA-approved product.
| Characteristic | Detail |
|---|---|
| Drug class | Triple receptor agonist (GLP-1 / GIP / glucagon) |
| Dosing frequency | Once weekly, subcutaneous |
| FDA status | Not FDA-approved; investigational / compounded |
| Phase 2 weight loss (48 weeks) | Up to ~24% body weight reduction reported |
| Phase 3 status | TRIUMPH-3 (cardiovascular outcomes) ongoing |
| Primary safety signals | GI adverse effects (nausea, vomiting, diarrhea) — mild to moderate |
Finding 1 — Phase 2 Weight Loss: What the Numbers Show
A 2025 systematic review and meta-analysis published in Proceedings (Baylor University Medical Center) — available via PubMed Central — pooled randomized controlled trials of retatrutide and reported striking weight loss benchmarks at 24 weeks compared to placebo.
- ≥5% weight loss: OR 43.34 (95% CI: 25.81–72.77; P <0.00001)
- ≥10% weight loss: OR 89.84 (95% CI: 42.31–190.77; P <0.00001)
- ≥15% weight loss: OR 46.93 (95% CI: 20.59–106.98; P <0.00001)
These are odds ratios relative to placebo, not absolute guarantees. Individual results vary based on starting weight, adherence, diet, activity, and metabolic profile. The meta-analysis noted low heterogeneity across the ≥10% and ≥15% thresholds, which strengthens the signal — but phase 2 sample sizes remain small compared to what phase 3 will provide.
A separate phase 2 trial reported in The New England Journal of Medicine found up to approximately 24% body weight reduction at 48 weeks in adults with obesity. For context, the benchmark for a transformative obesity drug has generally been set at ≥15% — retatrutide data consistently clears that bar in the phase 2 cohorts studied so far.
Finding 2 — How Retatrutide Compares to Semaglutide and Tirzepatide
Direct head-to-head RCTs between retatrutide and other GLP-1 agents don't yet exist. But the 2025 meta-analysis included contextual benchmarks from other trials:
| Agent | Dose | Population | Weight Loss Reported | Trial Duration |
|---|---|---|---|---|
| Dulaglutide | 4.5 mg | T2DM + obesity | ~5% | 40–52 weeks |
| Semaglutide | 2 mg | T2DM + obesity | ~7.2% | 40–52 weeks |
| Semaglutide | 2.4 mg (STEP 2) | Overweight/obese + T2DM | ~10.6% | 68 weeks |
| Tirzepatide | 15 mg (SURPASS-2) | T2DM | ~12% | 40 weeks |
| Retatrutide | High dose, Phase 2 | Overweight/obese + T2DM | Up to ~63% achieved ≥15% | 36 weeks |
| Retatrutide | Phase 2 | Obesity (no T2DM) | ~24% body weight | 48 weeks |
Important caveat: These numbers come from different trials with different populations, enrollment criteria, and durations. They are informative, not definitive head-to-head comparisons. Phase 3 data will be the real test.
The glucagon agonism in retatrutide is the likely driver of the incremental benefit. Glucagon receptor activation directly stimulates hepatic fat burning and energy expenditure in ways that GLP-1 alone does not. Whether this translates to better long-term cardiovascular outcomes is what TRIUMPH-3 is testing.
Already using or considering a GLP-1 therapy? Compare tirzepatide and semaglutide options at TelosRX to understand the current compounded landscape.
Finding 3 — Safety Profile Across Phase 2 Trials
The 2025 meta-analysis characterized retatrutide's safety profile as "appropriate" based on pooled phase 2 data. The most common adverse events were gastrointestinal, consistent with GLP-1 drug class effects:
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
Most GI events were mild to moderate. Dose-escalation protocols — starting low and titrating slowly — are the standard approach for managing GI tolerability with GLP-1 class agents, and the same principle applies to retatrutide protocols evaluated by providers.
The glucagon component introduces a theoretical consideration around muscle mass: glucagon is catabolic, which has raised questions about whether retatrutide could accelerate lean mass loss more than GLP-1-only agents. Phase 2 data on lean mass were not fully published at the time of the 2025 meta-analysis. This remains an active area of research. Anyone on a retatrutide protocol through a provider evaluation should discuss muscle preservation strategies, including resistance training and adequate protein intake.
For more on managing GLP-1 side effects in general, see GLP-1 Side Effects Management at TelosRX.
Finding 4 — Ongoing Phase 3 Research: TRIUMPH-3
Eli Lilly's TRIUMPH-3 trial is currently enrolling adults with obesity and established cardiovascular disease to assess retatrutide's effect on major adverse cardiovascular events (MACE). This mirrors the design of SUSTAIN-6 for semaglutide and SURPASS-CVOT for tirzepatide — both of which demonstrated cardiovascular benefit for their respective compounds.
TRIUMPH-3 is registered on ClinicalTrials.gov. Phase 3 results are expected in the coming years and will be the definitive evidence set for retatrutide's clinical positioning.
Phase 3 completion will also be relevant to FDA approval timelines. Until FDA approval of a branded retatrutide product, compounded versions remain not FDA-approved and are dispensed based on specific criteria under federal compounding law, subject to evaluation and prescription by a licensed provider.
What These Results Mean in Practice
Phase 2 data suggests retatrutide may achieve meaningfully greater weight loss than currently approved GLP-1 therapies at the doses studied. For patients who have reached a plateau on semaglutide or tirzepatide — or who need a more aggressive metabolic intervention — retatrutide's triple mechanism could represent a relevant option to discuss with a provider.
Key practical points based on the evidence:
- Retatrutide is compounded and not FDA-approved — it is dispensed through prescription, subject to provider evaluation
- Phase 3 data (cardiovascular outcomes) is pending
- GI side effects are manageable with dose titration
- Muscle preservation strategies are prudent given the glucagon component
- Asynchronous telehealth evaluation — no synchronous appointment required at TelosRX — makes access straightforward
If you've been researching GLP-1 options and want to understand whether retatrutide fits your profile, start with how GLP-1 mechanisms work — then complete your private evaluation at TelosRX.
Frequently Asked Questions
Is retatrutide FDA-approved?
No. As of 2026, retatrutide is not FDA-approved. It is available through compounding pharmacies as a not-FDA-approved compounded medication, dispensed by a licensed provider following evaluation. Phase 3 trials are ongoing; FDA approval may follow pending those results.
How does retatrutide differ from semaglutide?
Semaglutide is a GLP-1 receptor agonist. Retatrutide activates three receptors — GLP-1, GIP, and glucagon. The glucagon component adds direct lipolysis and hepatic fat oxidation that semaglutide does not provide. Phase 2 data shows larger weight loss with retatrutide, but these are different trials, not head-to-head comparisons.
What do phase 2 retatrutide trials show?
A 2025 systematic review pooling phase 2 RCT data found significantly higher odds of achieving ≥5%, ≥10%, and ≥15% weight loss versus placebo at 24 weeks. One phase 2 trial reported approximately 24% body weight reduction at 48 weeks. These are early-phase findings; phase 3 data will provide more robust evidence.
What are the main side effects of retatrutide?
Phase 2 data characterizes the safety profile as appropriate. The most common adverse events were gastrointestinal — nausea, vomiting, diarrhea, and decreased appetite — consistent with the GLP-1 drug class. These were generally mild to moderate and manageable with gradual dose titration.
Can I get retatrutide through TelosRX?
TelosRX offers an asynchronous online evaluation by a licensed provider who will review your health history and determine whether retatrutide or another GLP-1 compounded medication is appropriate for you. Approval is not guaranteed and is subject to clinical criteria. No synchronous appointment is required to start the process.
When will phase 3 retatrutide data be available?
The TRIUMPH-3 cardiovascular outcomes trial is currently enrolling. Phase 3 results are expected in the coming years. These results will inform FDA review and approval timelines for branded retatrutide. Until then, compounded retatrutide remains not FDA-approved.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.